SENS Senseonics Holdings, Inc.
Price Chart
Executive Summary
Senseonics presented positive real-world data at ADA 2026 showing Eversense 365 CGM delivers strong glucometrics and adherence across open-loop and closed-loop (twiist AID) systems over a full year, comparable or superior to competitors. The data validates the differentiated one-year implantable CGM but is incremental (not a regulatory or commercial catalyst).
Actionable Insight
This is a validation of competitive positioning but not a near-term catalyst. Monitor Senseonics' next quarterly report for commercial adoption rates and revenue growth, as well as potential partnership updates. Positive data may support long-term sentiment but is unlikely to move the stock alone.
Key Facts
- Data from 12,360 Eversense 365 sensors (open-loop) plus 153 closed-loop users with twiist AID system; average transmitter wear time 93.19% and median sensor wear time 99.46% for closed-loop.
- Mean Time In Range (TIR) of 66.16% for open-loop; closed-loop users achieved ~76.08% TIR and GMI of 6.78%, at the top end of reported real-world AID performance.
- More than 81% of users achieved hypoglycemic targets, comparing favorably to other CGM systems.
- No financial guidance, revenue, EPS, or commercial launch updates were disclosed.
Financial Impact
No financial impact quantified; the data supports product differentiation but does not alter near-term revenue trajectory.
Risk Factors
- No new revenue or guidance figures were provided; market may view this as incremental rather than transformative.
- Competition from traditional CGM players (Dexcom, Abbott, Medtronic) remains intense with higher adoption; Eversense 365's implantable model requires healthcare provider insertions, limiting patient adoption.
- Successful close of cross-filing actuarial amplifiers suggests that bundled press events (offering/activist context) historically amplifies moves, but this standalone data release lacks such context.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 6, 2026
6d ago
|
Press Release
| $6.95 awaiting T+20 | awaiting T+20 | — | $7.18 (+3.31%) |
|
May 7, 2026
5w ago
|
Press Release
| $5.03 $6.67 | ▲ +32.60% | ▲ +32.58% | $7.18 (+42.74%) |
|
May 1, 2026
6w ago
|
424B5
| $5.01 $6.84 | ▼ −36.53% | ▼ −30.88% | $7.18 (−43.31%) |
|
May 1, 2026
6w ago
|
Press Release
| $5.10 $6.84 | ▲ +34.12% | ▲ +28.83% | $7.18 (+40.78%) |
|
May 1, 2026
6w ago
|
Press Release
| $5.10 $6.84 | ▼ −34.12% | ▼ −28.83% | $7.18 (−40.78%) |
|
Apr 30, 2026
6w ago
|
424B5
| $5.10 $6.84 | ▼ −34.12% | ▼ −28.83% | $7.18 (−40.78%) |
|
Mar 13, 2026
13w ago
|
Insider Cluster
| $5.64 $6.72 | ▲ +19.15% | ▲ +15.56% | $7.18 (+27.30%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $6.83 $6.66 | ▼ −2.42% | ▲ +1.99% | $7.18 (+5.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access